anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Research is urgently needed to rigorously test a skills-based intervention for dating violence prevention among juvenile justice girls. Court-involved, non-incarcerated (CINI) girls represent a particularly high-risk group for dating violence exposure. This is due to the multiple risk factors they possess that have demonstrated associations with teen dating violence outcomes in other high-risk adolescent female populations. Despite the critical need for these young women to learn strategies that offset their heightened risk for involvement in coercive romantic relationships, no such evidence-based interventions exist for this population. The goal of the current study is to establish the efficacy of Date SMART (K23MH086328), a theoretically-driven skills-based intervention, in reducing dating violence, sexual risk behavior, and delinquency among girls in the juvenile justice system. Pilot data reveal that girls randomized to the Date SMART intervention spend significantly fewer days in violent relationships compared to girls randomized to the comparison condition. They also show improvements in condom use at last sex and reductions in delinquency. Moreover, the risk profile of adolescent girls who participated in the pilot trial is remarkably similar to the profile of adolescent girls involved in the juvenile justice system. Thus, Date SMART is uniquely suited for CINI girls. Despite the promise of Date SMART, the time lag from pilot testing to efficacy testing and final dissemination activities is protracted, as researchers fail to consider questions of effectiveness early on. Hybrid designs that retain core components of efficacy trials (randomization, controlled conditions) and essential elements of effectiveness research (e.g., participant diversity; standardized training procedures, attention to cost) can reduce time to implementation in the "real world." As such, investigators plan to test the efficacy of Date SMART on dating violence, sexual risk, and delinquency among 250 court-involved, non-incarcerated girls. Investigators will also gather effectiveness data from key stakeholders to determine how best to implement the program, train staff, and predict the cost of the program within the juvenile court. CINI girls, ages 14-17 (N= 12 juveniles for Phase I Intervention Run-Through; N=250 for Phase II Randomized Control Trial \[RCT\] study) will be recruited from the Rhode Island Family Court and Probation Departments and randomized to either the Date SMART (active) intervention (n=125) or a Health Promotion (control) condition (n=125). In Phase I (12 juveniles will be recruited to complete the Intervention Run-Through and research assessment once to allow testing of RCT intervention and assessment procedures prior to the RCT phase. In Phase II, 250 juveniles will be recruited and randomized at baseline and then re-assessed at 3, 6, 9 and 12 month post-intervention follow-ups.
The study will be a single center, double-blind, randomized, parallel group trial enrolling a minimum of 80 patients designed to determine the efficacy of eplerenone in subjects with diastolic heart failure. Prior to administration of study medication, a medical history, physical exam, blood draw, electrocardiogram, 2D echocardiogram, and cardiomyopathy questionnaire will be performed. Subjects will then be randomized to receive either eplerenone 25 mg once daily or placebo for 2 weeks. At the Week 2 visit all patients will be titrated up to the next dose (50 mg eplerenone once daily or placebo). Each study arm will have 40 subjects who will participate for 9 months. Follow-up assessments will be completed at 1 week, 2 weeks, 1 month, 3 months, 6 months, and 9 months.

Starting at the Month 1 visit, any subjects with uncontrolled blood pressure will be administered add-on therapy of HCTZ (starting dose of 12.5 mg daily, that may titrate up to 25 mg daily) and/or amlodipine (starting dose at 5 mg daily, that may titrate up to 10 mg daily). Any subject who receives add-on therapy must have their blood pressure checked within 2 weeks. Uncontrolled blood pressure may be treated by either increasing the add-on therapy dose or increasing the add-on therapy regimen to include both add-on drugs. Changes in add-on therapy require blood pressure checks within 2 weeks.
The invention comprises compounds of the general formula <FORM:0884623/IV (b)/1> in which R is hydrogen, an alkyl radical of 1-6 carbon atoms or a cycloalkyl radical of 3-6 carbon atoms, and non-toxic salts of these compounds with inorganic and organic bases. These compounds may be used in the production of X-ray contrast media, and they may be used either as free acids or as non-toxic salts such as the sodium, lithium, ammonium, calcium, methylglucamine, ethanolamine, diethanolamine, ethylamine, diethylamine, and methylglucosamine salts.  They may be obtained from the corresponding 2,4,6 - triiodo - 3 - amino - propionic acids by reaction with dimethyl formamide in presence of an acidic reaction promoter such as phosphorus oxychloride.  In an example, a -ethyl-b -(3-amino-2,4,6-triiodo-phenyl) -propionic acid is dissolved in dimethylformamide and treated dropwise with phosphorus oxychloride, the reaction mass is treated with acetone, and the hydrochloride of the amidine which separates is dissolved in hot water and treated with caustic soda to form the internal salt of a  - ethyl - b  - (dimethylamino - methyleneamino - 2,4,6 - triiodophenyl) - propionic acid.  The corresponding a -methyl compound is obtained in a similar manner.  Compounds containing other alkyl substituents, e.g. n-propyl or n-butyl, in the a -position of the propionic acid are referred to. In another example, b -(3-amino-2,4,6-triiodophenyl)-propionic acid is dissolved in a mixture of dimethyl formamide and chloroform and treated with phosphorus oxychloride to obtain b -(3-dimethylamino-methylene-amino-2,4,6-triiodophenyl)-propionic acid.ALSO:Compounds of the formula <FORM:0884623/VI/1> in which R is hydrogen, an alkyl radical of 1-6 carbon atoms, or a cycloalkyl radical of 3-6 carbon atoms, and non-toxic salts of these compounds, are used together with a carrier material to form X-ray contrast media.  Salts which may be used include the sodium, lithium, ammonium, calcium, methylglucamine, ethanolamine, ethylamine, and methyl-glucosamine salts.  The media may be prepared in the form of tablets, capsules, or dragees, and may be administered intravenously, perorally, or intraduodenally.  The active substances have low toxicity, and very good capacity for absorption and distribution.  In an example: a -ethyl - b  - (3 - dimethylamino - methylene - amino - 2,4,6 - triiodophenyl) - propionic acid is pasted with maize-starch paste, granulated and dried, then mixed with starch and magnesium stearate, and moulded into tablets.  The corresponding compounds having methyl, n-propyl or n-butyl as substituent in the a -position of the propionic acid may be used.  The granulated product may be formed into dragees by coating with sugar syrup and waxing.  In another example, the calcium salt of b -(3-dimethylamino - methyleneamino - 2,4,6 - triiodophenyl)-propionic acid is mixed with sugar, sodium lauryl sulphonate, sodium carboxymethyl cellulose, and flavouring.  The mixture may be taken with water.  If the active substance is to be filled into gelatine capsules on a machine, it may first be worked up with liquid paraffin to a fluid paste.
INTRODUCTION: The immunomodulatory properties of mesenchymal stromal cells (MSC) have been well-characterized in in-vitro and in-vivo models. We have previously shown that liver MSC (L-MSC) are superior inhibitors of T-cell activation/proliferation, NK cell cytolytic function, and macrophage activation compared to adipose (A-MSC) and bone marrow MSC (BM-MSC) in-vitro.
METHOD: To test these observations in-vivo, we infused these types of MSC into mice with unilateral renal artery stenosis (RAS), an established model of kidney inflammation. Unilateral RAS was induced via laparotomy in 11-week-old, male 129-S1 mice under general anesthesia. Control mice had sham operations. Human L-MSC, AMSC, and BM-MSC (5x105 cells each) or PBS vehicle were injected intra-arterially 2 weeks after surgery. Kidney morphology was studied 2 weeks after infusion using micro-MRI imaging. Renal inflammation, apoptosis, fibrosis, and MSC retention were studied ex-vivo utilizing western blot, immunofluorescence, and immunohistological analyses.
RESULTS: The stenotic kidney volume was smaller in all RAS mice, confirming significant injury, and was improved by infusion of all MSC types. All MSC-infused groups had lower levels of plasma renin and proteinuria compared to untreated RAS. Serum creatinine improved in micetreated with BM- and L-MSC. All types of MSC located to and were retained within the stenotic kidneys, but L-MSC retention was significantly higher than A- and BM-MSC. While all groups of MSC-treated mice displayed reduced overall inflammation and macrophage counts, L-MSC showed superior potency in-vivo at localizing to the site of inflammation and inducing M2 (reparative) macrophage polarization to reduce inflammatory changes.
DISCUSSION: These in-vivo findings extend our in-vitro studies and suggest that L-MSC possess unique anti-inflammatory properties that may play a role in liver-induced tolerance and lend further support to their use as therapeutic agents for diseases with underlying inflammatory pathophysiology.
* Talk with your healthcare provider regularly about whether you should continue taking PREMARIN.
  * If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you. The addition of a progestin is generally recommended for women with a uterus to reduce the chance of getting cancer of the uterus.
  * See your healthcare provider right away if you get vaginal bleeding while taking PREMARIN.
  * Have a breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
  * If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease.
Myocardial ischemia/reperfusion (MI/R) injury is the primary cause of postischemicheartfailure. The increased expression of Thioredoxin-interacting protein (TXNIP) has been implicated in MI/R injury, although the detailed mechanism remains incompletely understood. In the present study, we observed the up-regulation of the m6A mRNA methylation complex component Wilms' tumor 1-associating protein (WTAP) in MI/R mice, which led to the m6A modification of TXNIP mRNA and an increase in mRNA abundance. Knock-down of WTAP resulted in a significant reduction in the m6A level of TXNIP mRNA and down-regulated TXNIP expression. Moreover, exosomes engineered with ischemic myocardium-targeting peptide (IMTP) were able to deliver WTAP siRNA into ischemic myocardial tissues, resulting in a specific gene knockdown and myocardial protection. In summary, our findings demonstrate that the WTAP-TXNIP regulatory axis plays a significant role in postischemicheartfailure, and the use of engineered exosomes targeting the ischemic heart shows promise as a strategy for siRNA therapy to protect the heart from injury.
Before starting the study, the "Structured Patient Information Form," "Edmonton Symptom Diagnosis Scale," and "Oxford Happiness Scale Short Form" were applied to the patients. Then, the researcher gave the patients face-to-face, individual information about hand hygiene after contact with a live cat for approximately 15 minutes in the waiting room and offered them a "Live Cat Information Brochure." Patients were then asked to spend 20 minutes with a pet at home twice a week for 12 weeks. "Edmonton Symptom Diagnosis Scale" and "Oxford Happiness Scale Short Form" were applied to this group of patients three times: before, at the 6th week, and at the end of the 12th week of the study.
Trauma-related guilt is common and impairing among trauma survivors. Guilt is positively associated with severity of PTSD and depression symptoms, poorer psychosocial functioning and suicide risk. Although existing evidence-based trauma-focused PTSD treatments such as Prolonged Exposure (PE) are effective in treating PTSD and trauma-related guilt, many still experience symptoms or maintain their diagnosis after treatment. Preliminary research shows that a brief treatment targeting trauma-related and moral injury-related guilt and shame, Trauma Informed Guilt Reduction Therapy (TrIGR), can reduce guilt, PTSD, depression, and distress among Veterans and help them reengage with meaningful activities. Whether TrIGR is comparably effective to longer, more resource heavy evidence-based PTSD treatments disseminated across DoD and VA, like PE, is a critical question.

The proposed randomized clinical trial aims to determine if TrIGR is non-inferior to a first tier PTSD treatment, PE. Hypotheses are that 6 sessions of TrIGR will be non-inferior to 12 sessions of PE in reducing PTSD symptom severity among Veterans with PTSD who endorse trauma-related guilt. Secondary aims are to evaluate the hypotheses that TrIGR will be non-inferiority relative to PE in improving psychosocial functioning and depression symptoms and superior in reducing trauma-related guilt and shame. The study will also explore treatment differences in change in suicidal ideation and dropout.

Participants will be recruited from mental health clinics across three VAs. 158 Veterans who served since 9/11 and with PTSD and guilt from any type of trauma will be included. TrIGR will be administered over 6 weekly sessions (60-minutes each) and PE will be administered over 12 weekly sessions (90 minutes each). Blind assessors will evaluate participants at baseline and 8-, 16-, and 28 weeks after the first therapy session. Inclusion and exclusion criteria are minimized so that generalizability will be high.
S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
The system for intelligent in-vitro diagnosis and noninvasive heartbeat detection of big data of the mobile phone comprises an artificial intelligent heartbeat detection server and a heartbeat detection micro-message program. The artificial intelligence heartbeat detection server comprises a mobile phone model storage unit and is used for being connected with a commercial artificial intelligence server and a heartbeat detection small program. The heartbeat detection WeChat small program comprises an inclination angle detection unit, a position judgment unit, a heartbeat judgment unit, a graphical interface unit and a mobile phone microphone position checking and recording unit. The position judging unit is used for judging the probability of the mobile phone microphone aiming at the heart. The heartbeat judging unit is used for judging the probability of cardiac arrest of the patient. The mobile phone microphone position checking and recording unit comprises a checking button and an error correcting button and is used for obtaining a mobile phone model from a mobile phone of a user, marking a heartbeat detection micro-message program on a graphical interface unit according to the position of a mobile phone sound receiving microphone obtained from a mobile phone model storage unit according to the mobile phone model, and checking and confirming by the user.
RAC1 encodes a Rho family small GTPase that regulates actin cytoskeletal reorganization and intracellular signaling pathways. Pathogenic RAC1 variants lead to a neurodevelopmental disorder with diverse phenotypic manifestations, including abnormalities in brain size and facial dysmorphism. However, the underlying pathophysiological mechanisms have yet to be elucidated. Here, we present the case of a school-aged male who exhibited global developmental delay, intellectual disability, and acquired microcephaly. Through whole exome sequencing, we identified a novel de novo variant in RAC1, (NM_006908.5): c.92 A > G,p.(E31G). We then examined the pathophysiological significance of the p.E31G variant by focusing on brain development. Biochemical analyses revealed that the recombinant RAC1-E31G had no discernible impact on the intrinsic GDP/GTP exchange activity. However, it exhibited a slight inhibitory effect on GTP hydrolysis. Conversely, it demonstrated a typical response to both a guanine-nucleotide exchange factor and a GTPase-activating protein. In transient expression analyses using COS7 cells, RAC1-E31G exhibited minimal interaction with the downstream effector PAK1, even in its GTP-bound state. Additionally, overexpression of RAC1-E31G was observed to exert a weak inhibitory effect on the differentiation of primary cultured hippocampal neurons. Moreover, in vivo studies employing in utero electroporation revealed that acute expression of RAC1-E31G resulted in impairments in axonal elongation and dendritic arborization in the young adult stage. These findings suggest that the p.E31G variant functions as a dominant-negative version in the PAK1-mediated signaling pathway and is responsible for the clinical features observed in the patient under investigation, namely microcephaly and intellectual disability.
Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
BACKGROUND: Social jetlag is a circadian misalignment that arises from a discrepancy between activity/sleep schedules on school/work days and free days. This study explored the correlation between social jetlag and self-rated health (SRH) in a representative sample of Korea.
METHODS: This study included 8259 working population in the Korea National Health and Nutrition Examination Survey, 2016-2018. Social jetlag was calculated as the difference between the midpoint of sleep time on work day and work-free day. Five-point Likert scale of SRH was used to assess subjective health perception on general health conditions. Multiple logistic regression analysis was performed to calculate the odds ratios (ORs) and 95 % confidence interval (CI) for poor SRH in the 1-2 h or longer than 2 h social jetlag groups compared to that in the reference group (less than 1 h), after adjusting for age, sex, marital status, occupation, household income, and weekly working hours.
RESULTS: The proportions of those with <1 h, 1-2 h, >2 h of social jetlag were 63.80 %, 25.67 %, and 10.53 %, respectively. The risk of poor SRH increased as social jetlag increased. Greater social jetlag was significantly associated with an increased likelihood of reporting poor SRH. The adjusted ORs for the groups with social jetlag between 1 and <2 h, and >2 h were 1.100 (95 % CI = 0.935-1.295), and 1.503 (95 % CI = 1.097-1.727), respectively. Moreover, the OR trend was statistically significant (p for trend = 0.008).
CONCLUSION: This study found that social jetlag and poor SRH were significantly related in the Korean working population.
The present invention provides a Chinese medicine for curing foot and hand tinea, including the following raw materials with the weight portions: 20 of rhizoma polygonati, 30 of purple gromwell root, 30 of lightyellow sophora root, 20 of corktree bark, 20 of dittany bark, 15 of broom cypress fruit, 20 of common cnidium fruit, 10 of cortex pseudolaricis, 20 of amargosa bark, 15 of dried ginger and 10 of dried alum. The advantages of the present invention are toxic moisture dispersion, itch and perspiration alleviation, sterilization, reasonable prescription, simple production and low cost, which can be widely applied in foot washing house to prevent foot and hand tinea. The present invention is also convenient to carry and use in business trip and travelling. The present invention has the efficacy of invigorating spleen and replenishing qi, strengthening spleen and clearing toxic moisture, and sterilizing. The present invention has the advantages of obvious itch alleviating effect, rare recurrence after cure, obvious perspiration and odor elimination. The invention has no side effect and is applied for many years and well received.
A total of 60 CRC pateints' were enrolled in the study. CRC pateints' were treatment-naïve Egyptian patients' cohort admitted to the Clinical Oncology Clinic, National Cancer Institute (NCI), Cairo University, Cairo, Egypt. Male-to-female 1:1 (30/30) and their age range 24-76 years.
The cytotoxic T lymphocyte-associated antigen-4 (CTLA4) gene, a member of the immunoglobulin superfamily, is crucial for maintaining immune homeostasis and preventing autoimmune diseases. Studies have shown that polymorphisms in the CTLA4 gene are linked to an increased risk of brucellosis in humans, but its association with brucellosis in goats remains unexplored. In this study, the tissue expression profile of CTLA4 in goats was investigated, and the correlation between InDel polymorphisms in the CTLA4 gene and susceptibility to brucellosis in goats was examined. The findings reveal the widespread expression of CTLA4 in goat tissues, particularly in the spleen and testes. The tested goat populations presented genotypes insertion/insertion (II), insertion/deletion (ID), and deletion/deletion (DD) at both the P1 and P2 loci, and an association analysis revealed significant differences in the distribution of genotypes and allele frequencies at the P1 and P2 loci of the CTLA4 gene between the Brucella goat case and the control groups (p < 0.05). Specifically, compared with the II genotype, the P1 and P2 loci were significantly associated with an elevated risk of brucellosis development in goats under both the codominant (ID/II) and dominant (ID + DD/II) models (P1, p = 0.042, p = 0.016; P2, p = 0.011, p = 0.014). Additionally, haplotype analysis indicated that haplotypes IP1DP2, DP1IP2, and DP1DP2 were significantly associated with an increased risk of brucellosis in goats compared to the reference haplotype IP1IP2 (p = 0.029, p = 0.012, p = 0.034). Importantly, the Lipopolysaccharide (LPS) stimulation of peripheral blood monocytes and/or macrophages from goats with the II, ID, and DD genotypes resulted in increased CTLA4 expression levels in the II genotype, leading to a robust LPS-induced inflammatory response. Through bioinformatic analysis, the observed effect of the InDel locus on Brucella pathogenesis risk in goats could be attributed to the differential binding of the transcription factors nuclear factor kappaB (NF-κB) and CCAAT/enhancer-binding protein α (C/EBPα). These findings offer potential insights for breeding strategies against brucellosis.
PCT No. PCT/US91/02712 Sec. 371 Date Mar. 30, 1993 Sec. 102(e) Date Mar. 30, 1993 PCT Filed Apr. 19, 1991 PCT Pub. No. WO91/16869 PCT Pub. Date Nov. 14, 1991.Erodible bioadhesive drug delivery vehicles for use in delivering pharmaceutical compounds to the eye and similar physiological environments are disclosed. The drug delivery vehicles are formed of a homopolymer or copolymer of maleic anhydride or lower alkyl maleic anhydride incorporating a pharmaceutical compound in either a monolithic matrix or encapsulated form. The bioadhesive erodible drug delivery vehicles are configured to be retained in the eye following administration while providing specific erosion profiles allowing convenient drug delivery schedules ranging from hourly to daily or weekly intervals.